Senior Principal Scientist
Merck & Co., Inc.
Weifeng has been in the field of immunogenicity for more than 10 years. He is an active member of the AAPS neutralization antibody (NAb) workgroup and the EBF (European Bioanalysis Forum) NAb team; he is also co-leading the NAb assay drug tolerance subteam at AAPS. After joining Merck at the end of 2018, Weifeng is now leading the Scientific Strategy and Liaison Group within PDMB Regulated Bioanalytics.